Houlihan Lokey Advises Orifarm Group

Houlihan Lokey is pleased to announce that Orifarm Group A/S (Orifarm), a Danish-headquartered European pharmaceutical company with leading positions across generics, prescription medicines, and over-the-counter (OTC) healthcare products, has agreed to divest a carved-out products portfolio comprising its vitamins, minerals, and supplements (VMS) division and selected OTC products to STADA, a leading European consumer healthcare, generics, and specialty pharma company majority-owned by CapVest Partners LLP (CapVest). The transaction remains subject to customary antitrust clearance and other closing conditions.

The portfolio includes 16 attractive and long-established pharmacy-channel VMS and OTC brands with strong positions across the Nordics, Belgium, and Poland, including Nycoplus, Apovit, Magnecaps, and Vitrum. For Orifarm, the divestment allows the company to concentrate on pharmaceuticals and affordable medicines, where it has the greatest scale and can make the biggest difference for customers across Europe. For STADA, the acquisition adds well-known, consumer-trusted brands that can benefit from its dedicated consumer healthcare platform, broader retail reach, and investment in innovation.

Orifarm is a European leader in affordable medicines, driven by its purpose to create as healthy a day as possible for as many people as possible. Through innovative medicines, complex generics, and trusted OTC brands, Orifarm provides access to high-quality, affordable healthcare solutions addressing multiple therapeutic needs.

Headquartered in Odense, Denmark, and family-owned, Orifarm has a heritage dating back more than 30 years. Today, more than 2,300 employees work together to create value for patients, pharmacies, wholesalers, and hospitals. Securing access to affordable medicines across Europe is Orifarm’s core capability and where the group can make the biggest difference for its customers.

STADA Group is headquartered in Bad Vilbel, Germany. The group focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharma. Worldwide, STADA sells its products in more than 100 countries.

In financial year 2025, STADA achieved group sales of €4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation, and amortization (adj. cc EBITDA) of €961 million. As of 31 December 2025, STADA employed 11,670 people worldwide.

For Orifarm, the transaction supports its long-term strategic direction by strengthening its focus on core pharmaceutical activities, including parallel-traded medicines, niche generics, promotional prescription medicines, and OTC medicines. The agreement reinforces Orifarm’s focus on providing access to affordable medicines across Europe.

The portfolio consists of a leading range of European brands across VMS and OTC, including Nycoplus, the market-leading pharmacy VMS line in Norway; Apovit, the number one VMS range in Danish pharmacies; Magnecaps, a VMS and OTC muscle- and brain-health supplement brand in Belgium; and Vitrum, a broad VMS and OTC brand in Poland.

Houlihan Lokey served as the exclusive sellside financial advisor to Orifarm in connection with the divestment of a carved-out pharmacy-channel portfolio to STADA.

The transaction further builds on Houlihan Lokey’s strong track record advising pharmaceutical and consumer healthcare companies on strategic acquisitions, portfolio transactions, carve-outs, and divestments, and adds to a growing list of successful transactions across the pharmaceutical and consumer health sectors.

RELATED: Consumer, Healthcare, Mergers and Acquisitions